Phase I study of fenretinide (4-HPR) oral powder in patients with recurrent or resistant neuroblastoma: New Approaches to Neuroblastoma Therapy (NANT) Consortium trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback